RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer
RenovoRx today announced that the U.S. Food and Drug Administration (FDA) recently granted RenovoRx Orphan Drug Designation (ODD) of oxaliplatin for the treatment of pancreatic cancer.